{"id":4222,"date":"2026-06-11T09:28:58","date_gmt":"2026-06-11T16:28:58","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=4222"},"modified":"2026-06-11T09:29:01","modified_gmt":"2026-06-11T16:29:01","slug":"sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/","title":{"rendered":"Sanofi\u00a0\uff1aRiliprubart&#8217;s Phase III MOBILIZE Study (NCT06290128) to be Terminated"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">On June 10 local time, Sanofi announced the termination of the Phase III MOBILIZE study (NCT06290128) of Riliprubart in patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Riliprubart (SAR445088, BIVV020) is a humanized IgG4 monoclonal antibody that selectively inhibits activated C1 in the classical complement pathway of the innate immune system. By blocking C1, Riliprubart has the potential to suppress key inflammatory mechanisms driving demyelination and axonal damage in CIDP.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MOBILIZE was a Phase III, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Riliprubart in subjects with refractory chronic inflammatory demyelinating polyradiculoneuropathy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Buy <strong>Riliprubart<\/strong>&nbsp;from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On June 10 local time, Sanofi announced the termination of the Phase III MOBILIZE study (NCT06290128) of Riliprubart in patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP). Riliprubart (SAR445088, BIVV020) is a humanized IgG4 monoclonal antibody that selectively inhibits activated C1 in the classical complement pathway of the innate immune system. By blocking C1, Riliprubart [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":4223,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-4222","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sanofi\u00a0\uff1aRiliprubart&#039;s Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China<\/title>\n<meta name=\"description\" content=\"Sanofi\u00a0\uff1aRiliprubart&#039;s Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-\uff1ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi\u00a0\uff1aRiliprubart&#039;s Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Sanofi\u00a0\uff1aRiliprubart&#039;s Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-\uff1ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-11T16:28:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-11T16:29:01+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-12_002749_980.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Sanofi\u00a0\uff1aRiliprubart&#8217;s Phase III MOBILIZE Study (NCT06290128) to be Terminated\",\"datePublished\":\"2026-06-11T16:28:58+00:00\",\"dateModified\":\"2026-06-11T16:29:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/\"},\"wordCount\":138,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/\u5fae\u4fe1\u56fe\u7247_2026-06-12_002749_980.jpg\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/\",\"name\":\"Sanofi\u00a0\uff1aRiliprubart's Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/\u5fae\u4fe1\u56fe\u7247_2026-06-12_002749_980.jpg\",\"datePublished\":\"2026-06-11T16:28:58+00:00\",\"dateModified\":\"2026-06-11T16:29:01+00:00\",\"description\":\"Sanofi\u00a0\uff1aRiliprubart's Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/\u5fae\u4fe1\u56fe\u7247_2026-06-12_002749_980.jpg\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/\u5fae\u4fe1\u56fe\u7247_2026-06-12_002749_980.jpg\",\"width\":512,\"height\":512,\"caption\":\"Sanofi\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi\u00a0\uff1aRiliprubart&#8217;s Phase III MOBILIZE Study (NCT06290128) to be Terminated\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanofi\u00a0\uff1aRiliprubart's Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China","description":"Sanofi\u00a0\uff1aRiliprubart's Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-\uff1ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/","og_locale":"en_US","og_type":"article","og_title":"Sanofi\u00a0\uff1aRiliprubart's Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China","og_description":"Sanofi\u00a0\uff1aRiliprubart's Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-\uff1ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-11T16:28:58+00:00","article_modified_time":"2026-06-11T16:29:01+00:00","og_image":[{"width":512,"height":512,"url":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-12_002749_980.jpg","type":"image\/jpeg"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Sanofi\u00a0\uff1aRiliprubart&#8217;s Phase III MOBILIZE Study (NCT06290128) to be Terminated","datePublished":"2026-06-11T16:28:58+00:00","dateModified":"2026-06-11T16:29:01+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/"},"wordCount":138,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-12_002749_980.jpg","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/","url":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/","name":"Sanofi\u00a0\uff1aRiliprubart's Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-12_002749_980.jpg","datePublished":"2026-06-11T16:28:58+00:00","dateModified":"2026-06-11T16:29:01+00:00","description":"Sanofi\u00a0\uff1aRiliprubart's Phase III MOBILIZE Study (NCT06290128) to be Terminated - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-12_002749_980.jpg","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-12_002749_980.jpg","width":512,"height":512,"caption":"Sanofi"},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/sanofi-%ef%bc%9ariliprubarts-phase-iii-mobilize-study-nct06290128-to-be-terminated\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Sanofi\u00a0\uff1aRiliprubart&#8217;s Phase III MOBILIZE Study (NCT06290128) to be Terminated"}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=4222"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4222\/revisions"}],"predecessor-version":[{"id":4224,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4222\/revisions\/4224"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media\/4223"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=4222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=4222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=4222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}